A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia

Clinical Therapeutics

Volumn 24, Issue 4, 2002, Pages 605-615

  Sokol Jr , William N ^a   Sullivan, James G ^b   Acampora, Matthew D ^c   Busman, Todd A ^d   Notario, Gerard F ^d  

^a Health Research Institute   (United States)

^b Parkway Medical Center ^*  (United States)

^c Metrolina Nephrology Associates   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Clarithromycin extended release; Community acquired pneumonia; Fluoroquinolone; Trovafloxacin

Indexed keywords

CLARITHROMYCIN; TROVAFLOXACIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PNEUMONIA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SUSTAINED RELEASE PREPARATION; TASTE DISORDER; THORAX RADIOGRAPHY; VERTIGO; VOMITING;

EID: 0036245697     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85136-0     Document Type: Article

References (15)

1. Practice guidelines for the management of community-acquired pneumonia in adults
2. Prognosis and outcomes of patients with community-acquired pneumonia: A metaanalysis
3. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
4. Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention
5. Gatifloxacin
6. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia
7. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia
8. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
9. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia
10. Efficacy of clarithromycin against Mycoplasma pneumoniae
11. Clarithromycin in the treatment of community-acquired lower respiratory tract infections